Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5544895 | 0.99 | MEN1 (0.43) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104019 | 0.96 | MEN1 (0.49) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL6697326 | 0.96 | MEN1 (0.49) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104043 | 0.94 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL1273606 | 0.94 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL168983 | 0.94 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL4637586 | 0.92 | MEN1 (0.40) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL3257080 | 0.91 | MEN1 (0.45) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL14246460 | 0.90 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL6111495 | 0.90 | MEN1 (0.44) | MEN1MAPTKMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110088153-B | Composition, cured product, and laminate | DIC株式会社 | 2021-03-30 | — | — | CN | disclosed |
| US-20200325100-A1 | SUBSTITUTED OR UNSUBSTITUTED ALLYL GROUP-CONTAINING MALEIMIDE COMPOUND, PRODUCTION METHOD THEREFOR, AND COMPOSITION AND CURED PRODUCT USING SAID COMPOUND | DIC CORPORATION (JP) | 2020-10-15 | — | — | US | disclosed |
| US-20200109276-A1 | COMPOSITION, CURED PRODUCT AND LAMINATE | DIC CORPORATION (JP) | 2020-04-09 | — | — | US | disclosed |
| EP-3560968-A1 | COMPOSITION, CURED PRODUCT AND LAMINATE | DIC Corporation (JP) | 2019-10-30 | — | — | EP | disclosed |
| CN-110088153-A | Composition, cured product, and laminate | DIC株式会社 | 2019-08-02 | — | — | CN | disclosed |
| EP-3466993-A1 | SUBSTITUTED OR UNSUBSTITUTED ALLYL GROUP-CONTAINING MALEIMIDE COMPOUND, PRODUCTION METHOD THEREFOR, AND COMPOSITION AND CURED PRODUCT USING SAID COMPOUND | DIC Corporation (JP) | 2019-04-10 | — | — | EP | disclosed |
| CN-109312024-A | Maleimide compound containing substituted or unsubstituted allyl group, process for producing the same, and composition and cured product using the same | DIC株式会社 | 2019-02-05 | — | — | CN | disclosed |
| US-9458092-B2 | α-Substituted glycinamide derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-20160115119-A1 | alpha-SUBSTITUTED GLYCINAMIDE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2016-04-28 | — | — | US | disclosed |
| US-7220770-B2 | Heterocyclo-substituted imidazoles for the treatment of inflammation | KHANNA ISH K | 2007-05-22 | — | — | US | disclosed |
| US-6613789-B2 | Especially for treating arthritis, pain and fever | G. D. SEARLE & CO. | 2003-09-02 | — | — | US | disclosed |
| EP-0880504-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2003-02-20 | — | — | US | disclosed |
| EP-0772600-B1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1193265-A2 | A process for the preparation of 4-[2-(aryl or heterocyclo)-1H-imidazol-1-yl]benzenesulfonamides | G.D. Searle & Co. (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-0880504-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997027181-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-07-31 | — | — | WO | disclosed |
| EP-0772600-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5616601-A | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation | GD SEARLE & CO (US) | 1997-04-01 | — | — | US | disclosed |
| WO-1996003388-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HCK, IL4I1, AHR | MEN1 4859/4885MAPT 4717/4885KMT2A 3035/4885 |
| US-20160115119-A1 | alpha-SUBSTITUTED GLYCINAMIDE DERIVATIVE | TRPM8, GRM8, GRIN2A | MEN1 1273/4885MAPT 1896/4885KMT2A 1122/4885 |
| US-20200325100-A1 | SUBSTITUTED OR UNSUBSTITUTED ALLYL GROUP-CONTAINING MALEIMIDE COMPOUND, PRODUCTION METHOD THEREFOR, AND COMPOSITION AND CURED PRODUCT USING SAID COMPOUND | WASF2, FAR1, NOTUM | MEN1 47/4885MAPT 3636/4885KMT2A 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.